Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

•Post hoc analysis of niraparib efficacy in PRIMA by surgical timing and postoperative residual disease status.•Efficacy outcomes with niraparib treatment were similar regardless of surgical timing.•Niraparib demonstrated efficacy in both patients with visible and nonvisible residual disease at interval cytoreduction.